BioDelivery Sciences International
Market Cap
US$435.8m
Last Updated
2021/01/18 23:03 UTC
Data Sources
Company Financials +
Executive Summary
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has BioDelivery Sciences International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BDSI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BDSI's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-3.1%
BDSI
-0.08%
US Pharmaceuticals
-0.4%
US Market
1 Year Return
-26.1%
BDSI
3.5%
US Pharmaceuticals
19.5%
US Market
Return vs Industry: BDSI underperformed the US Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: BDSI underperformed the US Market which returned 19.6% over the past year.
Shareholder returns
| BDSI | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.1% | -0.08% | -0.4% |
| 30 Day | -5.1% | 4.5% | 2.3% |
| 90 Day | 30.2% | 10.9% | 12.7% |
| 1 Year | -26.1%-26.1% | 7.0%3.5% | 22.3%19.5% |
| 3 Year | 65.8%65.8% | 23.5%13.8% | 44.4%34.8% |
| 5 Year | 8.3%8.3% | 53.8%35.5% | 128.7%103.3% |
Long-Term Price Volatility Vs. Market
How volatile is BioDelivery Sciences International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Should BioDelivery Sciences International (NASDAQ:BDSI) Be Disappointed With Their 59% Profit?1 month ago | Simply Wall St
Is BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Popular Amongst Institutions?1 month ago | Simply Wall St
Does BioDelivery Sciences International (NASDAQ:BDSI) Have A Healthy Balance Sheet?Valuation
Is BioDelivery Sciences International undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BDSI ($4.31) is trading below our estimate of fair value ($59.96)
Significantly Below Fair Value: BDSI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BDSI is poor value based on its PE Ratio (28.1x) compared to the US Pharmaceuticals industry average (24.1x).
PE vs Market: BDSI is poor value based on its PE Ratio (28.1x) compared to the US market (21x).
Price to Earnings Growth Ratio
PEG Ratio: BDSI is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: BDSI is overvalued based on its PB Ratio (4.5x) compared to the US Pharmaceuticals industry average (4.4x).
Next Steps
Future Growth
How is BioDelivery Sciences International forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
35.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDSI's forecast earnings growth (35.4% per year) is above the savings rate (2%).
Earnings vs Market: BDSI's earnings (35.4% per year) are forecast to grow faster than the US market (21.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BDSI's revenue (18.3% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: BDSI's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDSI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has BioDelivery Sciences International performed over the past 5 years?
24.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDSI has a large one-off gain of $5.0M impacting its September 30 2020 financial results.
Growing Profit Margin: BDSI became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BDSI has become profitable over the past 5 years, growing earnings by 24.7% per year.
Accelerating Growth: BDSI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BDSI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: BDSI's Return on Equity (15.5%) is considered low.
Next Steps
Financial Health
How is BioDelivery Sciences International's financial position?
Financial Position Analysis
Short Term Liabilities: BDSI's short term assets ($168.6M) exceed its short term liabilities ($53.4M).
Long Term Liabilities: BDSI's short term assets ($168.6M) exceed its long term liabilities ($78.7M).
Debt to Equity History and Analysis
Debt Level: BDSI's debt to equity ratio (81.7%) is considered high.
Reducing Debt: BDSI's debt to equity ratio has reduced from 148.6% to 81.7% over the past 5 years.
Debt Coverage: BDSI's debt is well covered by operating cash flow (39.4%).
Interest Coverage: BDSI's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Balance Sheet
Next Steps
Dividend
What is BioDelivery Sciences International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BDSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BDSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BDSI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BDSI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BDSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Jeff Bailey (57 yo)
0.67
Tenure
Mr. Jeffrey Allen Bailey, also known as Jeff, has been Chief Executive Officer at BioDelivery Sciences International, Inc. since November 4, 2020. Mr. Bailey served as Interim Chief Executive Officer at Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Chief Commercial Officer | 3yrs | US$1.50m | 0.23% $ 1.0m | |
| CFO & Treasurer | 2yrs | US$1.12m | 0.012% $ 51.8k | |
| General Counsel | 2.17yrs | US$728.76k | no data | |
| Chief Medical Officer | 2.5yrs | US$1.01m | 0.0047% $ 20.4k | |
| CEO & Director | 0.67yr | no data | 0.035% $ 153.3k | |
| Senior Vice President of Operations | 3yrs | no data | no data | |
| Senior Vice President of Business Development | 1yr | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data |
2.2yrs
Average Tenure
57yo
Average Age
Experienced Management: BDSI's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 0.67yr | no data | 0.035% $ 153.3k | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.67yrs | US$75.00k | 0.22% $ 939.2k | |
| Vice Chairman | 4.25yrs | US$320.13k | 1.08% $ 4.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 2.67yrs | US$72.50k | 0.059% $ 257.7k | |
| Independent Director | 2.67yrs | US$62.50k | no data | |
| Independent Director | 3.08yrs | US$70.00k | 0.052% $ 228.4k |
2.7yrs
Average Tenure
58yo
Average Age
Experienced Board: BDSI's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BDSI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
BioDelivery Sciences International, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: BioDelivery Sciences International, Inc.
- Ticker: BDSI
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$435.788m
- Shares outstanding: 101.11m
- Website: https://www.bdsi.com
Number of Employees
Location
- BioDelivery Sciences International, Inc.
- 4131 ParkLake Avenue
- Suite 225
- Raleigh
- North Carolina
- 27612
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BDSI | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jul 2002 |
| BD5 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2002 |
Biography
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The compa...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/18 23:03 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.